US Edition
News from cancernetwork.com
Media Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top cancernetwork.com News
Breast Cancer · United StatesOn Thursday, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Co.’s (NYSE: LLY) Inluriyo (imlunestrant) for adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease progressed after at least one line of endocrine therapy (ET). The FDA approval is based on the results of the EMBER-3 trial in the patient populatio…See the Story
FDA Approves Eli Lilly's Drug For Advanced Breast Cancer - Eli Lilly (NYSE:LLY)
60% Center coverage: 5 sources
CancerA new phase III clinical trial finds that intensity-modulated radiation therapy (IMRT) and proton beam therapy resulted in similar quality-of-life outcomes and low rates of side effects for people with locally advanced oropharyngeal cancer.See the Story
Proton Therapy and IMRT Show Similar Outcomes in Head and Neck Cancer Trial
100% Center coverage: 2 sources
BARTRadiation therapy could be an underused tool to reduce pelvic relapse risk for patients with locally advanced, muscle-invasive bladder cancer, according to results of a new phase III randomized trial.See the Story
Post-Operative Radiation Therapy Reduces Pelvic Relapse in High-Risk Bladder Cancer
100% Center coverage: 1 sources
